Products for Research Use Only

Velneperit

CAT: 0804-HY-14423-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-14423-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Velneperit (S-2367) is an orally active neuropeptide Y (NPY) Y5 receptor antagonist that can penetrate the blood-brain barrier. Velneperit inhibits the appetite-stimulating and metabolism-inhibiting effects mediated by NPY. Velneperit selectively improves diet-induced obesity in mice. Velneperit enhances the expression of fear acutely by removing the inhibition of CeA Drd2 neurons. Velneperit can be used for the study of obesity[1][2][3].
CAS Number
342577-38-2
Product Name Alternative
S2367
UNSPSC
12352005
Hazard Statement
H302, H315, H320, H335
Target
Neuropeptide Y Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/Velneperit.html
Purity
99.21
Solubility
DMSO : ≥ 30 mg/mL
Smiles
FC(F)(F)C1=CN=C(NC([C@H]2CC[C@H](NS(=O)(C(C)(C)C)=O)CC2)=O)C=C1
Molecular Formula
C17H24F3N3O3S
Molecular Weight
407.45
Precautions
H302, H315, H320, H335
References & Citations
[1]Ishihara A, et al. A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice. Proc Natl Acad Sci U S A. 2006 May 2;103 (18) :7154-8.|[2]McCullough KM, et al. Cell-type-specific interrogation of CeA Drd2 neurons to identify targets for pharmacological modulation of fear extinction. Transl Psychiatry. 2018 Aug 22;8 (1) :164. |[3]Powell, A. G., C. M. Apovian, and L. J. Aronne. New drug targets for the treatment of obesity. Clinical pharmacology & therapeutics 90.1 (2011) : 40-51.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
NPY Y5 receptor